Bayer Announces Approval Of New Indication For Kerendia In The EU

The European Commission approved Kerendia (finerenone) for the treatment of adults with heart failure, granting Bayer EU marketing authorization. Kerendia is a selective, non-steroidal mineralocorticoid receptor antagonist; the approval strengthens Bayer's cardiovascular product portfolio and revenue visibility and should be modestly positive for Bayer shares (likely a small, single-digit percentage move).

Analysis

The European Commission approved Kerendia (finerenone) for the treatment of adults with heart failure, granting Bayer EU marketing authorization. Kerendia is a selective, non-steroidal mineralocorticoid receptor antagonist; the approval strengthens Bayer's cardiovascular product portfolio and revenue visibility and should be modestly positive for Bayer shares (likely a small, single-digit percentage move).